Comparison of serum anti-survivin antibody levels between benign and malignant lung tumor
10.3760/cma.j.issn.1008-6315.2011.05.021
- VernacularTitle:血清抗存活素抗体水平在肺部良恶性肿瘤中的对照研究
- Author:
Weihong ZHANG
;
Jingpu HOU
;
Guochen WANG
;
Zuosheng LI
- Publication Type:Journal Article
- Keywords:
Anti-survivin antibody;
non-small lung cancer;
Survivin;
Squamous carcinoma;
Adenocarcinoma;
Lung benign pathological change
- From:
Clinical Medicine of China
2011;27(5):509-511
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the serum anti-survivin antibody levels between benign and malignant lung tumor,thus to provide evidence for using anti-survivin antibody as an indicator in non-small cell lung cancer.Methods ELISA was used to measure the level of anti-survivin antibody in healthy population(control group,n=60),benign lung tumor patients(benign lung tumor group,n=60) and non-small cell lung cancer patients(non-small cell lung cancer group,n=60). Results The anti-surviving antibody did not express 11.7%(7/60) in the control group and almost no expression 20.0%(12/60) in the benign lung tumor group,with no significant difference between the two groups(P＞0.05).In the non-small cell lung cancer group,the anti-survivin antibody expressed in 41 patients,which was significantly higher than those in the benign lung tumor group(x2=38.352,P＜0.01).Conclusion Anti-survivin antibody does not express in the healthy population and the benign lung tumor patients,whereas shows high expression in non-small cell lung cancer.This finding indicates that anti-survivin antibody can provide important evidence for non-small cell lung cancer diagnosis,and can be used as an indicator for non-small lung cancer screening.
